NasdaqGM:AXSMPharmaceuticals
Axsome SUNOSI Patent Settlement Clarifies Exclusivity Window And Future Competition
Axsome Therapeutics and Alkem Laboratories have reached a settlement over patent litigation related to SUNOSI.
The agreement includes a defined date for potential generic SUNOSI entry, subject to regulatory review.
The resolution addresses a key intellectual property question around one of Axsome's commercial products.
For Axsome Therapeutics, ticker NasdaqGM:AXSM, this settlement comes at a time when the stock is trading at $181.21 and has returned 41.5% over the past year and 185.5% over...